In this discussion, Dave Ricks, CEO of Eli Lilly, shares insights on the company's groundbreaking weight-loss drugs, like Zepbound and terzepatide. He elaborates on their potential in treating addictive behaviors and combating the rising global obesity crisis. Ricks highlights the need for accessible treatments and the complexities of drug manufacturing. He also reflects on his career journey and the transformative impact these medications can have on patients' lives, emphasizing the importance of sustainable health changes.